The QualityStocks Daily Tuesday, February 14th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(EPAZ) $0.0106 +231.25%

NetworkNewsWire(AMST) $0.5098 +81.62%

The Stock Dork(BWV) $1.5600 +33.33%

The QualityStocks Daily Stock List

CVD Equipment (CVV)

Wall Street Resources, MarketBeat, TradersPro, StreetInsider, QualityStocks, CRWEFinance, Streetwise Reports, DrStockPick, Marketbeat.com, PennyToBuck, CRWEPicks, CRWEWallStreet, MarketClub Analysis, PennyOmega, SmarTrend Newsletters, StockHotTips, Outsider Club, Market Wrap Daily, BestOtc, TradingMarkets, TopStockAnalysts, The Street, Street Insider, Greenbackers, Zacks, StockMarketWatch, OTC Markets Group, Barchart, SmallCapVoice and FeedBlitz reported earlier on CVD Equipment (CVV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CVD Equipment Corporation (NASDAQ: CVV) (FRA: 0V3) is focused on designing, developing, manufacturing and selling process equipment and solutions which are utilized in the development and manufacture of coatings and materials for industrial and research applications.

The firm has its headquarters in Central Islip, New York and was incorporated in 1982, on October 13th by Leonard A. Rosenbaum. The firm serves consumers in the United States as well as internationally.

The company operates through the CVD Materials, SDC, Corporate and CVD segments. The corporate segment refers to the company’s administration activities which include anti-corrosion, customer support and process software services while the CVD materials segment provides material coatings for electronic, medical and aerospace applications. The SDC segment comprises of its ultra-high purity manufacturing division while the CVD segment is used for chemical vapor deposition equipment manufacturing. The company serves the solar photovoltaics, semiconductor, optoelectronics, nanomaterials, military, medical, glass coatings and aerospace markets.

The enterprise provides custom and standard fabricated quartz-ware used in various tools as well as its equipment. It also offers replacement and repair services for existing quartz-ware. In addition to this, the enterprise provides rapid thermal processing systems used in silicide formation. It also avails chemical vapor deposition systems which are utilized in researching, developing and manufacturing solar cells, carbon nanotubes and nanowires.

The company recently received a huge order from a major electric car battery material manufacturer in the U.S. With electric vehicle sales projected to grow significantly in the coming years, this contract will be helpful in extending the firm’s consumer reach in the sector and will also help bring in more opportunities and investments into the firm, which will have a positive effect on the company’s growth.

CVD Equipment (CVV), closed Tuesday's trading session at $14.85, up 16.9291%, on 288,900 volume. The average volume for the last 3 months is 334,952 and the stock's 52-week low/high is $3.68/$15.82.

SunLink Health Systems (SSY)

StreetInsider, QualityStocks, TradersPro, MarketClub Analysis, Wall Street Resources, CRWEWallStreet, StockOodles, Stock Preacher, Beacon Equity Research, MarketBeat, FeedBlitz, Greenbackers, INO Market Report, InvestorPlace, Marketbeat.com, PennyTrader Publisher, Zacks, Short Term Wealth, Street Insider and Penny Invest reported earlier on SunLink Health Systems (SSY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SunLink Health Systems Inc. (NYSE American: SSY) provides healthcare products and services in the southern U.S., with the primary focus being on community hospitals and related home care businesses and nursing homes.

The firm has its headquarters in Atlanta, Georgia and was incorporated in June 1959. It operates as part of the nursing homes and long-term care facilities industry, under the healthcare sector and the healthcare facilities and Svcs sub-industry. There are thirty seven firms under the company’s corporate family.

The company operates through the pharmacy and healthcare services segments. The former segment is focused on managing a specialty pharmacy business in Louisiana, providing non-institutional and institutional pharmacy services and durable medical equipment services and products, which comprise of the rental and sale of products for patient-administered home care, patients in institutional settings and institutional clients. This is in addition to providing retail pharmacy services and products. On the other hand, the latter segment is focused on operating a bed nursing home IT Service Company and bed community hospital. This segment also owns and operates other healthcare facilities, which are sometimes leased to 3rd parties and it owns unimproved lands.

The firm recently announced that its Trace Regional Hospital subsidiary planned to upgrade and expand its support areas, patient care and physical plant. Its COO noted that this move would allow the firm to meet the increasing demand for acute care hospital services, which would grow the firm’s revenue and boost popularity, which would encourage more investments into the firm.

SunLink Health Systems (SSY), closed Tuesday's trading session at $1.255, up 16.2037%, on 334,952 volume. The average volume for the last 3 months is 331,034 and the stock's 52-week low/high is $0.53045/$2.10.

MyMD Pharmaceuticals (MYMD)

MarketClub Analysis, Broad Street, QualityStocks and StocksEarning reported earlier on MyMD Pharmaceuticals (MYMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MyMD Pharmaceuticals Inc. (NASDAQ: MYMD) is a clinical stage pharmaceutical firm that is focused on the development, manufacture and supply of therapies that target aging and age-related ailments, sleeping disorders, anxiety, chronic pain and autoimmune diseases.

The firm has its headquarters in Tampa, Florida and was founded in 2014. It operates as part of the pharmaceutical manufacturing industry and serves consumers across the globe.

MyMD Pharmaceuticals is committed to extending the healthy lifespan of individuals through the therapies it develops. It is also involved in the development of a potent small molecule that acts on ROS (reactive oxygen species) through hydrogen peroxide modulation. It utilizes the hypothesis that there exists a robust relationship between the initiation and profession of autoimmunity and ROS accumulation.

The firm’s product pipeline includes a synthetic cannabidiol that provides potency and bioavailability in comparison with botanicals known as SUPERA-CBD, which has been developed to impede monoamine oxidase and target various key receptors like opioid receptors and CB2.The company’s SUPERA-CBD product is being developed to address the burgeoning CBD market, which includes CBD products that aren’t currently regulated as drugs and those that have been approved as drugs by the FDA. It also develops a therapeutic that helps manage conditions associated with immunometabolic dysregulation called MYMD-1. The candidate has been developed to treat longevity, aging and autoimmune diseases.

The company is scheduled to merge with Akers Biosciences Inc. soon, which will help to further advance the company’s pipeline of drug candidates. This merger will also bring in new investors, which will boost the company’s growth.

MyMD Pharmaceuticals (MYMD), closed Tuesday's trading session at $1.93, up 15.9159%, on 331,034 volume. The average volume for the last 3 months is 24,950 and the stock's 52-week low/high is $0.90/$6.15.

Magnis Energy Technologies (MNSEF)

We reported earlier on Magnis Energy Technologies (MNSEF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Magnis Energy Technologies Ltd (OTCQX: MNSEF) (ASX: MNS) (FRA: U1P) is a battery technology firm that is focused on exploring for and developing mineral properties in Australia, the United States and Tanzania.

The firm has its headquarters in Sydney, Australia and was incorporated in 2005, on July 4th. Prior to its name change in November 2018, the firm was known as Magnis Resources Ltd. It operates as part of the electrical equipment and parts industry, under the industrials sector. The firm serves consumers around the globe.

The company's operating segments include Lithium-ion Battery Investment Australia; Lithium-ion Battery Investment USA; and Graphite Exploration and Development Tanzania. It generates most of its revenue from the Graphite Exploration and Development Tanzania segment. The company’s subsidiary, Imperium3 New York, Inc. (iM3NY), operates a Gigawatt-scale Lithium-ion battery manufacturing project in Endicott, New York. iM3NY has commercialized C4Vs patented cathode chemistry to produce green credentialed lithium-ion battery cells for use in both electric vehicles and battery energy storage systems. The company also has a joint venture and lithium-ion research and development (R&D) technology partner, Charge CCCV LLC (C4V).

The enterprise primarily explores for natural flake graphite used in batteries for storing electrical energy. It holds a 100% interest in the Nachu project, which is a large-scale natural flake graphite project located in south-east Tanzania.

The company supports and accelerates the adoption of electric vehicles and renewable energy storage critical for the green energy transition. This will significantly encourage investments into the company while also bolstering its overall growth.

Magnis Energy Technologies (MNSEF), closed Tuesday's trading session at $0.305, even for the day, on 24,950 volume. The average volume for the last 3 months is 1,500 and the stock's 52-week low/high is $0.1621/$0.432.

Itafos Inc. (MBCF)

We reported earlier on Itafos Inc. (MBCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Itafos Inc. (OTC: MBCF) (CVE: IFOS) (FRA: 82E) is a phosphate and specialty fertilizer platform firm that is focused on production and sale of monoammonium phosphate (MAP), MAP with micronutrients, superphosphoric acid, merchant-grade phosphoric acid, ammonium polyphosphate, single superphosphate (SSP), SSP with micronutrients and sulfuric acid.

The firm has its headquarters in Houston, Texas and was incorporated in 1999, on July 9th by Antenor F. Silva and Peter J. Marrone. Prior to its name change in December 2016, the firm was known as MBAC Fertilizer Corp. It operates as part of the agricultural inputs industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates through the Itafos Conda, Itafos Arraias, Development and Exploration and Corporate segments. The Itafos Conda segment is involved in the production and sale of monoammonium phosphate (MAP), MAP with micronutrients, superphosphoric acid, merchant-grade phosphoric acid, and specialty products including ammonium polyphosphate. The Itafos Arraias segment provides single superphosphate (SSP), SSP with micronutrients, premium PK compounds, and excess sulfuric acid. On the other hand, the Development and Exploration segment comprises of activities related to Itafos in the following locations: Farim, Paris Hills, Santana, Mantaro, and Araxá. The Corporate segment includes support, administrative, and financing activities.

The firm recently announced its latest financial and operational results, with its CEO noting that they were focused on the long-term growth of the business and evaluating strategic alternatives of its assets. This will help create shareholder value and bolster the firm’s overall growth.

Itafos Inc. (MBCF), closed Tuesday's trading session at $1.22, off by 0.813008%, on 1,500 volume. The average volume for the last 3 months is 3,650 and the stock's 52-week low/high is $1.03/$3.13.

Corus Entertainment (CJREF)

MarketBeat, SmarTrend Newsletters, StocksEarning, Zacks, StreetInsider, InvestorPlace and Daily Profit reported earlier on Corus Entertainment (CJREF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Corus Entertainment Inc. (OTC: CJREF) (TSE: CJR.B) (LON: 0UR4) (FRA: 9CO) is a media and content firm that operates conventional and specialty television networks and radio stations.

The firm has its headquarters in Toronto, Canada and was incorporated in 1998, on March 3rd by James Robert Shaw. It operates as part of the entertainment industry, under the communication services. The firm serves consumers around the globe, with a focus on those in Canada.

The enterprise operates through the Television and Radio segments. The Television segment consists of specialty television networks, pay television services, conventional television stations and the Corus content business. It operates 33 specialty television networks and 15 conventional television stations. This segment is also involved in the production and distribution of films and television programs, and animation software; and merchandise licensing and book publishing activities. In addition, the television segment provides social digital agency and social influencer networks, as well as media and technology services. On the other hand, the Radio segment operates 39 radio stations that include a network of news-talk radio stations, as well as classic rock, country, new rock, and contemporary music formats. The television segment generates a majority of the enterprise’s revenue. Geographically, it derives most of its revenue from Canada. Its primary brands include Global Television, W Network, OWN: Oprah Winfrey Network Canada, HGTV Canada, Food Network Canada, History, Showcase, Adult Swim, National Geographic, Disney Channel Canada, YTV, and Nickelodeon Canada.

The company, which recently announced its latest financial results, remains focused on long-term growth and advancing its strategic plan and priorities. This may bring in additional revenues into the company while also creating value for its shareholders.

Corus Entertainment (CJREF), closed Tuesday's trading session at $1.581, off by 1.1875%, on 3,650 volume. The average volume for the last 3 months is 3,000 and the stock's 52-week low/high is $1.41/$4.16.

Tidewater Midstream and Infrastructure (TWMIF)

MarketBeat reported earlier on Tidewater Midstream and Infrastructure (TWMIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tidewater Midstream and Infrastructure Ltd. (OTC: TWMIF) (TSE: TWM) (FRA: TL5) is a diversified midstream and infrastructure firm that is focused on natural gas, natural gas liquids (NGLs) and crude oil operations and processing plants located in the Edmonton, Deep Basin and Montney regions of Alberta and British Columbia.

The firm has its headquarters in Calgary, Canada and was incorporated in 2015, on February 4th by Tobias J. McKenna. It operates as part of the oil and gas midstream industry, under the energy sector. The firm serves consumers in North America.

The company operates through its subsidiary, Tidewater Renewables Ltd, which is a multi-faceted, energy transition firm focused on the production of low carbon fuels. Its business segments comprise of Midstream, Downstream, Marketing and extraction and other segments. The company generates maximum revenue from the marketing and extraction segment.

The firm is involved in gathering, processing, and transporting natural gas and NGLs; crude oil refining and refined products marketing; NGL extraction and marketing; and crude oil marketing and transportation. It also produces refined products, including gasoline, low sulfur diesel, and other products; produces and sells crude oil, natural gas, and NGLs; and rents railcars, as well as operates export terminals and storage facilities.

The company, which recently declared shareholder dividends for this last quarter, remains focused on profitably growing and creating shareholder value through acquiring and developing renewable energy infrastructure. This will bring in additional revenues as well as investments into the company.

Tidewater Midstream and Infrastructure (TWMIF), closed Tuesday's trading session at $0.8051, even for the day. The average volume for the last 3 months is 227,630 and the stock's 52-week low/high is $0.7118/$1.3471.

FiscalNote (NOTE)

SmartMoneyTrading, Money Wealth Matters and MarketBeat reported earlier on FiscalNote (NOTE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FiscalNote Inc. (NYSE: NOTE) is a technology and data firm that is focused on the delivery of critical legal data and insights globally.

The firm has its headquarters in Washington, District of Columbia and was incorporated in 2013 by Gerald Yao and Timothy Hwang. It operates as part of the information technology services industry, under the technology sector. The firm serves consumers across the globe.

The company turns insights into action to help clients stay ahead of rapidly evolving political, corporate, and regulatory environments. Its mission is to empower organizations with mission-critical insights and the tools to turn them into action. The company provides a range of brands, including Home to CQ, Equilibrium, FrontierView, Oxford Analytica, and VoterVoice, among others.

The enterprise combines AI technology, machine learning and other technologies with analytics, workflow tools, and expert research. It delivers that intelligence through its suite of public policy and issues management products, as well as powerful tools to manage workflows, advocacy campaigns, and constituent relationships. The enterprise provides solutions based on need, role, industry and issue. It serves a customer base that includes businesses comprising Fortune 100 companies, government agencies, law firms, professional services organizations, trade groups, and non-profits.

The firm recently acquired Dragonfly Eye Ltd, a geopolitical and security intelligence provider based in the U.K. This move will not only extend the firm’s consumer reach but also open it up to new growth and investment opportunities, which will positively influence shareholder value.

FiscalNote (NOTE), closed Tuesday's trading session at $3.45, off by 1.7094%, on 227,947 volume. The average volume for the last 3 months is 348,402 and the stock's 52-week low/high is $3.22/$12.30.

FSD Pharma Inc. (HUGE)

QualityStocks, Schaeffer's, BUYINS.NET, StockMarketWatch, MarketClub Analysis, Penny Dreamers, InvestorPlace, CFN Media Group and AwesomeStocks reported earlier on FSD Pharma Inc. (HUGE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse. “Alcohol intoxication is a common presentation in many patients who visit hospital emergency rooms, and I see this during every one of my shifts,” said Dr. Albert Wong, a member of FSD Pharma’s expert advisory committee and a psychiatrist in the emergency department at the Centre for Addiction and Mental Health in Toronto, Canada. “These presentations can require substantial time and effort to manage. Anything that could accelerate recovery from alcohol intoxication would free up valuable health care resources and provide additional treatment options for alcohol use disorders.”

To view the full press release, visit https://ibn.fm/Yj3Ye

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, an ultra-micronized PEA formulation, for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information, visit the company’s website at www.FSDPharma.com.

FSD Pharma Inc. (HUGE), closed Tuesday's trading session at $1.74, up 4.8698%, on 348,402 volume. The average volume for the last 3 months is 127,621 and the stock's 52-week low/high is $0.6181/$1.75.

Sonnet BioTherapeutics Holdings Inc. (SONN)

QualityStocks, StockMarketWatch, MarketBeat, BUYINS.NET, The Stock Dork, The Online Investor, OTCtipReporter and InvestorsUnderground reported earlier on Sonnet BioTherapeutics Holdings Inc. (SONN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company developing innovative targeted biologic drugs, is reporting the pricing of its underwritten public offering; the offering consists of 13,888,888 shares of common stock or common stock equivalents, including prefunded warrants to purchase shares of common stock in lieu of shares of common stock and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock. According to the announcement, the common stock shares (or prefunded warrants in lieu thereof) are being combined and sold with one investor warrant enabling the purchase of two shares of common stock at a combined offering price of $1.08. Total gross proceeds of the offering will be approximately $15 million, before Sonnet pays typical underwriting discounts and commissions and offering expenses. The company plans to use funds from the offering for R&D, including clinical trials, as well as general corporate purposes and working capital.

To view the full press release, visit https://ibn.fm/3IA34

About Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action. Known as FHAB (fully human albumin binding), the technology utilizes a fully human single chain antibody fragment (“scFv”) that binds to and “hitch hikes” on human serum albumin (“HAS”) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines. For more information about the company, visit www.SonnetBio.com

Sonnet BioTherapeutics Holdings Inc. (SONN), closed Tuesday's trading session at $0.92, off by 2.1277%, on 129,367 volume. The average volume for the last 3 months is 321,963 and the stock's 52-week low/high is $0.908/$9.3716.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, Daily Trade Alert, TopPennyStockMovers, The Online Investor, VectorVest, PoliticsAndMyPortfolio, Small Cap Firm, SmallCapVoice, Eagle Financial Publications and Cabot Wealth reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In an intriguing effort to demonstrate an alternative to conventional recycling, an energy startup in California has converted 1,300 electric vehicle (EV) batteries into storage capsules for solar power. The project, according to B2U Storage Solutions, the company behind the technology, will significantly reduce solar storage costs. Additionally, it will aid in lowering the carbon footprint of EV batteries, which includes manufacturing and mining costs that harm the environment.

On Feb. 7, 2023, the company announced that it had 25 MWh of stored solar energy stored in 1,300 batteries from Nissan and Honda connected to a solar energy campus in Lancaster. Nearby solar panels provide daytime battery charging for the facility. After that, when solar energy prices are higher at night, the company sells electricity back to the facility.

According to the CEO, Freeman Hall, the project, which sold power into a wholesale market, is thought to be the only one of its kind and generated $1 million in 2022.

Although the project is still in its infancy, the new solar storage offers a useful home for the millions of used batteries that will be generated by the transition to EV transportation in the future. Additionally, it is a more economical method of deploying the massive battery capacity required to store wind and solar energy during winter.

While some detractors might argue that 25 MWh isn’t much — the largest solar storage facilities in the world produce more MWh — the B2U’s facility simply shows that used EV batteries can be used to store solar energy at a useful scale. With the help of B2U technology, EV batteries can be used as a whole without needing to be disassembled first. The benefit? It essentially eliminates the costs associated with repurposing and makes the technology a practical operation moving forward.

The startup is looking to build more projects in Texas and California.

In the meantime, battery recycling companies such as Lithion and Redwood Materials are gaining traction, and we may see other applications emerge. Redwood Materials spent $3.5 billion last year building a massive, new manufacturing and recycling facility in South Carolina to produce enough parts to power a million electric vehicles.

Automakers might also look into comparable technology to aid in reducing the carbon footprint of their production processes.

It is anticipated that the supply of used batteries will exponentially increase as long-time owners of electric vehicles from manufacturers such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) produce newer models. Many of these batteries could be used as energy storage alternatives.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Tuesday's trading session at $0.9462, off by 0.4%, on 325,766 volume. The average volume for the last 3 months is 706,487 and the stock's 52-week low/high is $0.5715/$2.44.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom, Marketbeat.com, MarketClub Analysis, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, PennyOmega, BestOtc, Schaeffer's, StockHotTips, TraderPower, PennyToBuck, StockOodles, Street Insider, The Street and TopPennyStockMovers reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

After decades of prohibition by most territories, psychedelics are finally seeing a surge in interest among the scientific and mainstream communities. Initial research into the potential risks and benefits of psychedelic drugs has revealed that they may be able to alleviate the symptoms of a variety of mental health disorders.

While this research is still in its infancy, it has shown that psychedelics have significant potential as mental health treatment, especially when paired with psychotherapy. Stakeholders, entrepreneurs and anyone else interested in psychedelics will have the chance to learn everything about them during the upcoming Psychedelic Sciences conference.

The conference is slated to run from June 19–23, 2023, at the Colorado Convention Center and will feature dozens of speakers, including prominent broadcaster Tim Ferris; topics on the agenda cover nearly every facet of the nascent psychedelics industry.

Those who attend will be in for five days of workshops, networking opportunities, lectures and presentations from some of the most notable names in psychedelic drug research, venture capital, drug advocacy and more.

In addition to covering some of the more technical aspects of psychedelics and how they affect the human body, the conference will cover general topics such as health, wellness, business, science and supporting services.

The conference is founded and hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), one of the most significant research organizations studying psychedelic drugs. Previous conventions organized by MAPS were private affairs involving professionals within the psychedelic industry; this event will be the first time the general public will be granted access to the convention.

Organizers expect at least 10,000 individuals to attend the convention this year, which is three times more than the 3,000 professionals who attended the convention in 2017. Psychedelics Science executive producer Benjamin Greenzweig stated that with the burgeoning psychedelics industry constantly evolving, this year’s conference would dedicate significant time and resources toward covering the business aspect of psychedelics, ethical business models for success and state-level regulations.

Overall, the conference will be geared toward educating attendees on a range of topics regarding psychedelics. According to a preliminary schedule, attendees will learn about drug reform, ethnobotany, indigenous perspectives on hallucinogens, psychedelic use in religious settings, addiction, substance abuse and equal access to psychedelic treatment.

Conference registration begins at $755 for the general public, with health and scientific practitioners paying $995 and business founders, entrepreneurs and executives will pay $1,695.

These conferences generally boost the profile of the psychedelics industry and all players in that space, including company such as atai Life Sciences N.V. (NASDAQ: ATAI), as the general public and others gain awareness and added insight into this growing sector.

atai Life Sciences N.V. (ATAI), closed Tuesday's trading session at $1.79, even for the day, on 710,867 volume. The average volume for the last 3 months is 24,334 and the stock's 52-week low/high is $1.45/$6.32.

The QualityStocks Company Corner

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

A deal being negotiated between Newmont Mining,the top gold producer in the world, and top Australian minerNewcrest Mining could give birth to a global gold superpower if itis successful. Newmont Corporation confirmed early last week thatit had submitted a $17 billion proposal to purchase 100% of Newcrest Mining’s issued share capital. If thetakeover offer is successful, it would result in a merger betweentwo of the largest gold miners in the world and set new standardsfor responsible and sustainable gold mining.The takeover deal would be the largest such deal in Australianhistory and would create a global gold superpower unrivaled by anyother gold producer across the world. Although the offer is 4.7% higher than a previously rejected proposal, some analysts believe that Newmont will have to increase its bidfor it to be successful. If this deal is inked, other industryplayers such as Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) are unlikely to be affected since each has its own segment of themarket that it serves.

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) today announced results of additional modeling of ground magneticdata and completion of an initial Induced Polarization/Resistivitysurvey (“IP/Res”) on the Casiterita property adjoining the IskaIska Silver-Tin Polymetallic property to the southwest. The newdata, combined with previous magnetic modeling and borehole IP/Ressurveys (“BHIP”) on Iska Iska, have significantly enhanced theunderstanding of the overall geological environment on bothproperties and outlined major new targets for exploration on theoptioned Casiterita. “Geophysics continues to be a very effectiveexploration tool at Iska Iska and now at the Casiterita property,”said Eloro’s EVP, Exploration Dr. Bill Pearson, P.Geo. “We planadditional BHIP and IP/Res lines in the Porco area north of themagnetic anomaly to tie this area to the major conductive zonefurther south. Drilling has commenced, initially in the Porco andMina 1-2 areas, then will move into the Casiterita property to testthis major target for a potential tin porphyry once old roads arerehabilitated and drill pads prepared.” To view the full pressrelease, visit https://ibn.fm/Y5egp

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.

Projects

Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Tuesday's trading session at $2.5, up 2.1246%, on 24,834 volume. The average volume for the last 3 months is 149,407 and the stock's 52-week low/high is $2.09/$4.46.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologieswith a focus on monitoring and modulating the immune system, todayannounced the formation of a U.S.-based wholly owned subsidiary,Pearsanta Inc. The move intends to accelerate the expansion ofAditxt’s second program, AditxtScore(TM), through future strategicrevenue and growth-oriented transactions. According to the update,Anthony Voorhies, currently the head of the AditxtScore(TM)division, will serve as president of Pearsanta. Voorhies has over20 years of clinical diagnostics and healthtech industry experienceand, under his leadership, the AditxtScore(TM) division hassuccessfully grown from inception to commercialization and revenuesin just under two years. “Pearsanta is well positioned for growthin 2023,” Voorhies said in the news release. “Pearsanta’s focus ison expanding our innovation platforms through a diversified productoffering and pipeline while driving revenue growth fromreimbursement and cash channels. Pearsanta will also focus onenhancing operational capabilities and efficiencies, throughautomation and new delivery systems to rapidly scale our businessand fulfill a growing market demand for personalized and precisemedicine.” To view the full press release, visit https://ibn.fm/pw7vO

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.


Aditxt Inc. (NASDAQ: ADTX), closed Tuesday's trading session at $1.369, up 7.7953%, on 149,407 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.46/$.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelicsto Therapeutics(TM), is reporting on its third quarter performanceas well as recent business highlights; the report is for the periodended Dec. 31, 2022. In the report, the company noted that it hadreceived approval from an independent ethics committee in theNetherlands to begin the first-in-human dosing of its CYB004through a protocol amendment to its ongoing phase 1 CYB004-E trial;CYB004 is the company’s proprietary deuteratedN,N-dimethyltryptamine (“DMT”) molecule. The company is also makingprogress on its phase 1/2a clinical trial evaluating CYB003 for thepotential treatment of major depressive disorder (“MDD”); CYB003 isCybin’s proprietary deuterated psilocybin analog for the potentialtreatment of MDD. The company anticipates releasing an interimreadout from the trial at its upcoming virtual R&D Day, whichis slated for Feb. 28, 2023. In addition, the company notedpromising results from a feasibility study that is evaluatingKernel Flow wearable technology. Financial information for Q3includes cash for the company totaling C$22.5 million as of Dec.31, 2022, and C$20 million as of Feb. 14, 2023; net loss of C$10.7million for third quarter ended December 31, 2022, down from lastyear’s reported net loss of C$17.2 million in the same period; andcash-based operating expenses coming in at C$11.1 million with cashflows used in operating activities totaling C$10.8 million for thequarter. “Looking ahead, we remain well-positioned to deliver onmultiple near-term clinical milestones and data catalysts acrossour pipeline programs,” said Cybin CEO Doug Drysdale in the pressrelease. “With interim data expected imminently for our phase 1/2astudy of CYB003 and approval to begin dosing CYB004 in humans, thestage is set for continued momentum and strong clinical execution.With a cash runway that will support upcoming value-drivingclinical milestones, we will continue our focus on clinicalexecution with the goal of ultimately bringing improved therapeuticoptions to patients in need.” To view the full press release,visit https://ibn.fm/91O2D

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.41, up 0.588813%, on 790,194 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2649/$1.14.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Cannabis reform activists and users recently scored a major winafter an Oklahoma federal judge ruled that banning cannabis users from owning firearms is unconstitutional. Although tens of millions of Americans now have access tocannabis via state-legal medical and recreational markets, federallaw still prohibits the production, distribution, sale and use of marijuana. As aresult, cannabis users often find themselves facing repercussionsfor consuming cannabis per their home state’s regulations. One suchconsequence is that individuals who use marijuana are prohibited by federal law from purchasing and owning firearms, a right that is afforded to all Americans through the SecondAmendment. The new ruling came after Oklahoma native Jared MichaelHarrison, who had been arrested after a traffic stop where policeofficers discovered cannabis and a loaded revolver in his car,filed a legal challenge against the country’s federal firearms legislation. His attorneys argued that Harrison’s right to bear arms wasviolated after a federal law made it illegal for “unlawful users oraddicts of controlled substances.” As more states allow qualifyingresidents to grow their own marijuana, more contradictions betweenstate and federal rules will be unearthed even as opportunities arecreated for manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX) that make the necessary equipment for indoor grows.

Anyone who has consumed alcohol and used marijuana will tell youthat one core difference between the two is that, unlike alcohol,cannabis does not induce a hangover. While you may feel a little foggy and lethargic following a night of cannabis consumption, you will feel none ofthe uncomfortable symptoms associated with an alcohol hangover. However, since anecdotalaccounts of how cannabis doesn’t leave users with a hangover rarelycount in the grand scheme of things, researchers have repeatedlyset out to determine whether or not marijuana has a hangover effectvia the scientific method. A review of 20 such studies by University of Sydney researchers has further challenged theidea that cannabis has hangover effects and raised questionsregarding the legitimacy of drug policies that punish certainindividuals for prior cannabis use. The researchers analyzed 20studies that reviewed the effects of cannabis eight hours after consumption; they focused on assessing the performance of subjects to detectany hangover effects. The author of the study, Danielle McCartney,stated that most of these studies did not observe any next-dayeffects after using cannabis. McCartney, a research fellow at theUniversity of Sydney’s Lambert Initiative for Cannabinoid Therapeutics, then noted that although some research did observe some next-dayeffects, those studies had substantial limitations. This concerncomes as even more jurisdictions are allowing qualifying patientsto grow their own medical marijuana. As a result, there is anexpanding market for requisite indoor cultivation equipment fromenterprises such as Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Tuesday's trading session at $0.38, even for the day, on 359 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2005/$1.25.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

  • Coyuchi’s product line features textiles made using 100%organic cotton – with more than 200,000 active customersaveraging a repeat purchase rate of 35%
  • The United States organic bedding market was valued at $231.8million in 2020 and is expected to reach $1.2 billion globallyby 2027
  • Coyuchi pushes the organic textile market forward throughcircular initiatives, including the Coyuchi Climate Council andC4: The California Cotton & Climate Coalition
  • Coyuchi guarantees the highest environmental and ethicalstandards through numerous certifications such as The GlobalOrganic Textile Standard (“GOTS”), Fair Trade Certified, andMADE SAFE(R)
  • Coyuchi is providing investment opportunities through aRegulation A+ public offering

The millennial generation was the first to make purchasing based onpositive societal impact popular – with 83% wanting the brands theypurchase from to align with their values and beliefs (https://ibn.fm/DpacM). Coyuchi, the gold standard in sustainable luxury home goods, uses 100%organic cotton in its textiles. It was built on four foundationalpillars: protect the planet, innovate circular design, livesustainably, and enrich the community – which is why the companyhas experienced record growth, with 200,000 active customersaveraging a repeat purchase rate of 35%.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

chart

GeoSolar Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight GeoSolar Technologies Inc.

  • EVs are only doing so much to affect climate change; housesaccount for 33% of all carbon emissions in U.S.
  • GeoSolar Technologies SmartGreen(TM) Home system is azero-carbon solution that uses a combination of greentechnologies to eliminate the need for fossil-fuel energy
  • SmartGreen(TM) households have been constructed in Colorado,where its geothermal heat pump system helped achieve some ofthe highest HERS scores ever

With climate change front and center, industries are innovating andmaking changes wherever possible to slash carbon emissions to meetglobal warming targets of 1.5 °C above pre-industrial levels. Rapidgrowth in electric vehicle sales is making a difference, but thereal opportunity to move the needle resides in a far lesserdiscussed topic: homes. More succinctly, the heat pumps that keeppeople comfortable inside, an opportunity that is at the heart ofthe business model of GeoSolar Technologies (“GST”).

GeoSolar Technologies Inc. (“GST”) is a Colorado-based climate technology company and the creator of the Smart Green Home® system for newly built and existing residences and commercial buildings. The company is focused on revolutionizing the way we heat, cool and power homes with 100% natural energy sources. Its patent-pending integrated system harnesses energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels.

In a GST home, the sun’s energy is captured on the roof to generate all of the electricity required. Additionally, the consistent climate of the earth is used to keep the home at a perfect temperature year-round, and the company’s proprietary air purifying unit ensures that the air inside the home is safe and healthy.

GST’s home technology has been installed in multiple test homes in Colorado and achieved exceptional results, including some of the most impressive energy efficiency ratings (HERS) in the industry.

GeoSolar Technologies is currently accepting investment as part of a Regulation A+ offering. Everyone* can invest now for as little as $300. For more information, visit the company’s profile on Manhattan Street Capital and review its Offering Circular.

GeoSolar Technologies Inc. (“GST”) has been qualified by the U.S. Securities and Exchange Commission (SEC) to conduct a Regulation A+ capital raise. GST is already a publicly traded company who makes quarterly and annual filings with the SEC and is subject to quarterly PCAOB audits. This is the first time shares of GeoSolar Technologies are being made available for public purchase. Upon completion of this Regulation A+ offering, the company intends to seek a listing of its stock.

 

The Decarbonization Movement

Soaring and unstable energy/fuel costs continue to highlight the importance of rethinking the traditional approach to powering homes, from top to bottom. While most everyone is well aware of the remarkable, multi-trillion-dollar opportunity the electric vehicle transformation offers to investors (in addition to the benefits to the climate problem), few recognize that the all-electric home market is as large as electric vehicles and equally important to reducing carbon emissions.

U.S. energy expenditures clocked in at $3,891 per person in 2018, leading to estimated spending of $1.3 trillion on energy that year alone. Despite this, fewer than 3% of U.S. homes are currently powered by solar. This number is poised to increase exponentially as both new and existing residences transition to zero carbon models.

GST estimates that if all the homes in America were powered by its technology, carbon pollution could be reduced by an estimated 1.9 trillion pounds per year, greatly reducing the negative impacts on our climate.

GeoSolarPlus®

The GeoSolarPlus (“GSP”) system combines solar power, geothermal ground-sourced energy and other clean energy technologies into one fully integrated system.
Key benefits of the GSP system include:

  • Making a real planet-changing difference in reducing air pollution
  • Eliminating or significantly reducing homeowners’ future utility bills
  • Enjoying lifetime energy independence and protection from price escalation and energy shortages
  • Eliminating greenhouse gas emissions from operation of home and daily life
  • Increasing home value
  • An integrated design for seamless operation of renewable energy systems
  • Maintaining a significantly healthier living environment
  • Leveraging existing renewable energy tax credits and electrification incentives
  • Creating stable jobs capable of supporting families in the decarbonized future

Click here to learn more about how GeoSolarPlus works.

Management Team

The GST leadership and management team includes some of the world’s most experienced and respected leaders in the fields of decarbonization and sustainable homes.

Stone Douglass is the Chairman and CEO of GST. He is a seasoned, 30-year public company executive and former Chairman and CEO of the Piper Aircraft Company.

Brent Mosbarger is the company’s Co-Founder and leads its commercial operations. He is a highly respected solar engineer whose experience includes roles with Chevron Energy’s green operations and serving as project manager and executive for a $400 million solar/geothermal innovation project.

Peter Romenesko is a Senior Strategic Advisor with GST. He brings to the company considerable experience as an engineer and large-scale project manager for Johnson Controls and Siemens.

Dr. Norbert Klebl is the company’s Co-Founder and Development Director. Recognized as one of the world’s leading experts in the field of zero-carbon innovation, he is a former McKinsey partner of 16 years with an MBA from Columbia.

Dar-Lon Chang is GST’s Director of New Product Development. Prior to joining GST, he had a 16-year career with ExxonMobil Energy Research. He received his PhD in engineering from the University of Illinois.

* Must be over 18, certain states are not currently available and will be added soon.


Recent News

chart

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

  • Insufficient critical mineral supplies could drive priceshigher amid copper shortages according to recent Forbes report
  • AZMCF’s Kay Mine Deposit has a historic resource estimate of“proven and probable reserves” of copper, gold, zinc, andsilver according to a 1982 report by Exxon Minerals (1)
  • During 2022, AZMCF received drill permits for Kay Mine Centraland Western targets, completed approximately 33,000 meters ofcore drilling, and initiating drilling on targets outside thedeposit
  • Fully-funded to complete the remaining Kay Mine Phase 2 programof 8,600 meters (budget of USD$2.7 million), as well as 76,000meters (budget of USD$24 million) planned for Phase 3 whichwill primarily test two large targets west of the Kay MineDeposit
  • Drilling at the large Western Target, located 1,200 meters westof the Kay Mine Deposit, scheduled to begin Q1 2023

Arizona Metals (TSX: AMC) (OTCQX: AZMCF), a mineral exploration company, started 2023 on a positivetrajectory with plans to begin exploring outside its flagship KayMine copper-gold-zinc-silver asset located in Yavapai County,Arizona.

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Vision Energy Corp. (OTCQX: AZMCF), closed Tuesday's trading session at $3.495, off by 2.4922%, on 20,840 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.30/$5.60.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

The American Cancer Society estimates that around 9,910 children under the age of 15 will be diagnosedwith cancer this year. Pediatric cancer is the second largest cause of death in children up to 14 years of age in the United States, and thedisease is expected to take the lives of 1,040 children under 15years in 2023. According to the World Health Organization, around 400,000 children aged 0 to 19 years of age are estimated to develop cancer worldwide annually.Advancements in medicine have allowed physicians to detectpediatric cancer earlier and avoid treatment delays, resulting in around 85% of pediatric cancer patients surviving for five years or more after diagnosis. Now recentresearch has revealed that pediatric oncologists often do notdiscuss prognostic information with patients and caregivers after a cancer diagnosis. Prognostic information is data that patients need to make fullyinformed decisions about their medical condition. As many companiessuch as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) develop cancer treatments that are more effective and have fewerside effects, chances are that clinicians will be more comfortablediscussing the prognosis of pediatric cancers with the concernedparties such as caregivers and the patients themselves since theoutlook may be better given those future treatment options.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $1.8, off by 10.3318%, on 36,817 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.7901/$16.50.

Recent News

Cepton Inc. (NASDAQ: CPTN)

The QualityStocks Daily Newsletter would like to spotlight Cepton Inc. (NASDAQ: CPTN).

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that it will provide a business update andrelease its financial results for the fourth quarter and full year2022 following the close of the market on Tuesday, March 14, 2023.Cepton will host a conference call and webcast at 2:30 p.m. PT(5:30 p.m. ET) that same day. Interested parties may join the callby dialing 1-877-300-8521 (toll-free) or 1-412-317-6026(international) and visiting Cepton’s Investor Relations page to access the live webcast. A telephonic replay will beavailable approximately two hours after the live call and untilMarch 28, 2023, and can be accessed by dialing 1-844-512-2921(toll-free) or 1-412-317-6671 (international) and entering accesscode 10175817. To view the full press release, visit https://ibn.fm/1zydu

Cepton Inc. (NASDAQ: CPTN) is a provider of state-of-the-art, intelligent, lidar-based solutions serving a range of markets, including automotive (ADAS/AV), smart cities, smart spaces and smart industrial applications. General Motors (NYSE:GM) has granted a series production award for Cepton’s lidar, the biggest such award to date in the automotive space. Cepton’s is the lidar component of GM’s Ultra Cruise autonomous driving platform. By leveraging its patented Micro Motion Technology (MMT®) lidar platform, the company develops reliable, scalable and cost-effective solutions that deliver long-range, high-resolution 3D perception for smart applications.

Cepton was established in 2016 by co-founders Dr. Jun Pei and Dr. Mark McCord. The company is headquartered in San Jose, California, and serves a fast-growing customer base through an international presence spanning North America, Germany, Japan, India and China.

Micro Motion Technology (MMT®)

Cepton was built from the ground up to meet key lidar industry challenges for mass market adoption. This company’s portfolio of proprietary technology is uniquely aimed at facilitating this industry growth through a combination of performance, reliability, affordability and design integration.

Key among its innovations is MMT®, a mirrorless, frictionless, rotation-free 3D imaging platform designed specifically for lidars. Its benefits for OEMs and system integrators include:

  • Reliability – The durable design uses common, easily attainable materials.
  • Versatility – The platform is capable of achieving near- to ultra-long range with a wide field of view.
  • Efficiency – MMT® features a compact form factor, low power usage and inexpensive components.
  • Scalability – Its simple design means that scale-up to high manufacturing volumes is easily attainable.

Because of their compact form factor, Cepton lidars are embeddable and ideally suited for advanced driver-assistance system (ADAS) integration, whether behind windshield, in headlamp or in fascia.

Agreement with KOITO

KOITO Manufacturing Co. Ltd., the world’s premier Tier 1 auto lighting supplier, originally started an evaluation of Cepton’s MMT® based lidars in 2018. In 2020, KOITO made an investment in Cepton aimed at accelerating the company’s development and enabling KOITO’s industrialization of high-performance and high reliability lidar sensors for ADAS and autonomous vehicle (AV) applications.

Through this collaboration, Cepton was able to secure the largest ADAS lidar series production award[1] with General Motors as a sole source in the automotive space. The award covers GM vehicles for the initial period of 2023-2027.

On August 5, 2021, the two companies deepened their relationship when KOITO committed to invest a further $50 million in Cepton’s business through its participation in a Private Investment in Public Equity (PIPE) offering of shares of common stock of Growth Capital Acquisition Corp. in connection with Cepton’s recent merger.

Collaboration with GM

On July 13, 2021, Cepton announced that it had secured an ADAS lidar series production award from a leading, Detroit-based global automotive OEM – the biggest lidar production award by any OEM to any lidar company. It was later clarified that the OEM was General Motors, and Cepton’s lidar is part of GM’s ADAS Ultra Cruise system.

GM is “expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars.” As such, the agreement marks the potential for “an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.”

On July 28, 2021, Ford Motor Company (NYSE: F) distributed an article on Medium noting, “Ford has been engaged with Cepton almost since their inception in 2016, both for R&D collaboration and small-scale deployments. Cepton LiDAR are deployed in some of [Ford’s] smart city projects. Based on Ford’s guidance, Cepton delivered a custom version of their LiDAR to enable R&D on advanced ADAS features.”

Market Outlook

Driven by increasing development and adoption in automobile safety applications, environmental mapping and 3D-modeling, the global lidar market is forecast to experience considerable growth over the coming years. A research report published by MarketsAndMarkets suggests that the sector will grow to an estimated $3.4 billion by 2026, achieving a CAGR of 21.6% over the next five years.

The report further highlights increasing investments in lidar startups by automotive giants as a driver of growth opportunities in the sector, particularly in North America.

In 2020, ground-based lidar accounted for the lion’s share of the overall lidar market, and this trend is expected to continue as the automotive sector continues to rapidly advance adoption across the full spectrum of vehicle classes. One factor not to be underestimated is the high barrier of entry and the exceptionally long time required for automotive OEMs to vet and award a production win to a lidar company. It is a commonly held view that the over 50 lidar companies will inevitably coalesce into a handful serving all OEMs.

Cepton, having a head start through its established partnership with leading global OEM GM, is uniquely positioned to capitalize on this market growth in the years to come.

Management Team

Cepton’s founder-led team is made up of lidar industry pioneers with decades of collective experience across advanced lidar and imaging technologies.

Jun Pei, Ph.D., is the company’s CEO and Co-Founder. He is a technology specialist with a focus in optics and electronics. Prior to founding Cepton, Dr. Pei founded AEP Technology, a firm focused on developing advanced 3D optical instruments. He received his Ph.D. in electrical engineering from Stanford University.

Mark McCord, Ph.D., is Cepton’s CTO and Co-Founder. Prior to founding Cepton, he led advanced development at KLA-Tencor. Dr. McCord also formerly served as an associate professor at Stanford University, where he earned his Ph.D. in electrical engineering.

Winston Fu, Ph.D., is the company’s CFO. Dr. Fu is the founder of Silicon Valley venture capital firm LDV Partners. Prior to joining Cepton, he served as CFO and Chairman of Active-Semi before its acquisition. Dr. Fu has also helped to build many technology companies as an entrepreneur and/or board member. He received his Ph.D. in applied physics from Stanford University, as well as an MBA from the Kellogg School of Management at Northwestern University.

[1] Largest known ADAS lidar series production award based on number of vehicle models awarded

Cepton Inc. (NASDAQ: CPTN), closed Tuesday's trading session at $1.2, off by 0.826446%, on 80,098 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.01/$80.16.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $1.74, off by 3.8674%, on 113,881 volume. The average volume for the last 3 months is 110,870 and the stock's 52-week low/high is $1.23/$35.50.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Tuesday's trading session at $3.08, off by 1.2821%, on 71,400 volume. The average volume for the last 3 months is 69,353 and the stock's 52-week low/high is $0.62/$9.795.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.

Fr8University

Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Tuesday's trading session at $0.347, off by 3.6111%, on 1,789,011 volume. The average volume for the last 3 months is 1.789M and the stock's 52-week low/high is $0.1799/$5.126.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.